# Adrenal Insufficiency Induced by Continued Abiraterone Acetate Use in a Prostate Cancer Patient in Remission: The Dangers of Unmonitored Long-Term Therapy Without Corticosteroids

## TL;DR

A prostate cancer patient developed adrenal insufficiency after long-term use of abiraterone acetate without corticosteroids, highlighting the need for monitoring.

## Contribution

Highlights the rare but serious risk of adrenal insufficiency from unmonitored abiraterone acetate use in prostate cancer patients.

## Key findings

- Adrenal insufficiency occurred in a prostate cancer patient using abiraterone acetate long-term without corticosteroids.
- The case underscores the importance of monitoring and concurrent corticosteroid use to prevent endocrine side effects.

## Abstract

This case report presents a rare occurrence of adrenal insufficiency induced by Zytiga (abiraterone acetate) in a patient with high-risk localized prostatic adenocarcinoma. Abiraterone acetate is a potent, selective and irreversible CYP17A1 inhibitor and is commonly used in the treatment of prostate cancer, but it can cause various endocrine side effects, especially if not used concurrently with the appropriate treatment. The clinical implications of this adverse event and management strategies are discussed here in this case report to raise awareness about this potential risk in patients with prostate cancer undergoing treatment with abiraterone acetate, especially when used in an erroneous manner without monitoring.